NasdaqGS:AMGNBiotechs
Amgen Stock Leads 3 Cardiovascular Pharma Picks After Novo Nordisk Trial Miss
A failed late stage heart drug trial at Novo Nordisk, with shares in Copenhagen down 8.6% and U.S. ADRs down 9.8% in premarket trading, has pushed cardiovascular pipelines into the spotlight. When a high profile project like ziltivekimab does not deliver a meaningful reduction in major cardiovascular events, attention often shifts to other companies exposed to the same news. This article walks through 3 stocks from our Cardiovascular Pharma Stocks With Upside From Novo Nordisk Setback...